| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 4 Jun 2025 | 31 May 2025 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/06/2025 inter alia to consider and approve To Consider & declare final dividend on the paid-up equity share capital of the Company for the Financial Year 2024-2025 Outcome of the meeting of the Board of Directors held on Wednesday, June 04, 2025 The 1/- each Board fully recommended a Final Dividend of Rs. 0.01/- (1%) per equity share of Rs. This paid (subject to deduction of tax, if any) for the financial year 2024-25, General shall be paid subject to the approval of the shareholders at the ensuing Annual Meeting of the Company. (As Per BSE Announcement Dated on 04.06.2025) | ||
| Board Meeting | 29 May 2025 | 16 May 2025 |
| Audited Results Outcome of the meeting of the Board of Directors held on Thursday May 29, 2025 Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve Audited financial result for the quarter and financial year ended on 31st March, 2025 along with the Auditors Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (As Per BSE Announcement dated on 16.05.2025) Audited Financial Statements for the quarter and year ended on March 31, 2025 (As per BSE Announcement Dated on 29/05/2025) | ||
| Board Meeting | 29 Mar 2025 | 29 Mar 2025 |
| Intimation of change in Secretarial Auditor of the company | ||
| Board Meeting | 26 Mar 2025 | 26 Mar 2025 |
| Outcome of the meeting of Independent directors held on today to consider the agendas as attached. | ||
| Board Meeting | 14 Feb 2025 | 3 Feb 2025 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve The Un-audited Financial Results of the Company for the Third quarter and Nine months ended on 31st December 2024 of the current financial year 2024-25 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015. Outcome of Board Meeting held today i.e. on 14th February, 2025 and 1. submission of Un-audited Financial Results of the Company for the Quarter and Nine months ended on 31st December, 2024. 2. Appointment Mr. Jay Gandhi, as Internal Auditor for FY 2024-25, The brief information as required under Regulation 30 of SEBI (LODR) regulations, 2015 for the said matter is attached as Annexure A. 3. Appointment of Ms. Shilpa Shah (Practising Company Secretary), as Secretarial Auditor for FY 2024-25, The brief information as required under Regulation 30 of SEBI (LODR) regulations, 2015 for the said matter is attached as Annexure B. (As Per BSE Announcement Dated on 14.02.2025) | ||
| Board Meeting | 29 Jan 2025 | 24 Jan 2025 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2025 inter alia to consider and approve Subdivision/ Stock Split of Equity Shares of the Company subject to approval of the shareholders the Company and other necessary approvals Outcome of Board Meeting held today i.e. on January 29, 2025 pursuant to Regulation 30 of SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on: 29/01/2025) | ||
| Board Meeting | 9 Jan 2025 | 4 Jan 2025 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/01/2025 inter alia to consider and approve To offer and issue of equity shares of the Company by way of a rights issue to eligible shareholders of the Company as on the record date (to be decided at a later date) for an amount not exceeding ? 36 crore in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended and other applicable laws (the Rights Issue). In connection with our earlier correspondence dated 4th January, 2025 wherein the Company intimated about the Board meeting scheduled to be held on Thursday, 9th January, 2025, we would like to inform the Exchange and all Stakeholders that certain matters, including the matters relating to Right Issue which were originally scheduled to be transacted at the ensuing Board meeting have now been deferred for being considered by the Board. The Company will intimate in due course and in accordance with the SEBI LODR regulations about the date of the Board meeting at which the offer and issue of equity shares of the Company, will be considered. (As Per BSE Announcement Dated on: 09/01/2025) | ||
| Board Meeting | 14 Nov 2024 | 7 Nov 2024 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Intimation of Board Meeting under Regulation 29 and 33 of SEBI (LODR) Regulations 2015 to be held on Thursday 14th November 2024 To consider and approve the Un-audited Financial Results of the Company For the Second Quarter and half year ended on 30th September 2024 ol the current F.Y 2024-25 pursuant to Regulation 33 of the SEBI (LODR) Regulations 2015. Outcome of Board Meeting held today i.e. on 14th November, 2024 and submission of Un-audited Financial Results of the Company for the Second Quarter and Half Year ended on 30th September, 2024. (As per BSE Announcement Dated on 14/11/2024) | ||
| Board Meeting | 25 Oct 2024 | 25 Oct 2024 |
| APPOINTMENT OF SHEETAL SHAH AS DIRECTOR AND RITU KAPOOR AS INDEPENDENT DIRECTOR IN THE MEETING HELD ON FRIDAY, OCTOBER 25, 2024. | ||
| Board Meeting | 28 Sep 2024 | 23 Sep 2024 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/09/2024 inter alia to consider and approve Shukra Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on Saturday September 28 2024. Board meeting conducted to consider rights issue and approve the draft offer letter Board meeting conducted to consider and approve Rights issues and approve draft offer letter to consider and approve right issue and approve draft offer letter (As per BSE Announcement Dated on 28/09/2024) | ||
| Board Meeting | 12 Aug 2024 | 3 Aug 2024 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve unaudited financial results for the quarter ended June 30 2024 Approval of Financial results for the quarter ended June 30, 2024 (As Per Bse Announcement Dated on 12.08.2024) | ||
| Board Meeting | 23 Jul 2024 | 23 Jul 2024 |
| Increase in the authorised share capital of company. | ||
| Board Meeting | 10 Jul 2024 | 10 Jul 2024 |
| Resignation of Mr. Mehul Patel from the post of Chief Financial Officer of the Company with effect from July 10, 2024, Appointment of Ms. Anar Jayesh Patel (DIN: 02588388 ), as Additional Director (Whole-time Director), liable to retire by rotation, designated as Executive Director for a period of 5 years with effect from July 10, 2024 to July 09, 2029 and appointment of Mr. Jitendra Somchand Shah ( DIN: 01609325), as an Additional Director categorized as Non - Executive Independent Director of the Company, for a term of 5 consecutive years w.e.f. July 10, 2024 to July 9 2029 | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.